Cp-ADC / Lantern Pharma - LARVOL DELTA

Lantern Pharma Reports First Quarter 2024 Financial Results and Business Highlights (Businesswire) - "The company recently announced a artificial intelligence (AI)-driven collaboration to optimize the development of a protein disulfide isomerase (PDI) inhibitor drug candidate, XCE853, for a variety of novel and targeted cancer indications. The collaboration is leveraging RADR’s AI-based capabilities...and define potential combination regimens to sharpen and accelerate XCE853’s drug development strategy. Lantern Pharma is receiving equal IP co-ownership and drug development rights in newly discovered biomarkers, novel indications, and use for new pharmacological strategies for XCE853...Lantern expects to pursue additional biopharma and technology partnerships during 2024 to further advance and commercialize the RADR AI platform....Lantern expects to move towards IND development of its ADC program during 2024 with a focus on select solid tumors that are unresponsive or refractory to current therapies."

IND • Licensing / partnership • Oncology • Solid Tumor